Iovance Biotherapeutics (IOVA) Reports In-Line Q4 EPS

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q4 EPS of ($0.64), in-line with the analyst estimate of ($0.64).

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
• Iovance Biotherapeutics to Present at Upcoming Conferences